Ronan Flippot

  • Citations Per Year
Learn More
Deregulation of FGF (fibroblast growth factor)/FGFR (fibroblast growth factor receptor) signalling leads to the promotion of several oncogenic mechanisms: proliferation, epithelial-mesenchymal transition, cytoskeleton modifications, migration and angiogenesis. Deregulation of this pathway is reported in various cancers at early stages, and can therefore be(More)
Metastases are present in one third of renal cell carcinomas at diagnosis. The overall survival duration in metastatic renal cell carcinoma is approximately 22 months, which underlines the need for more effective systemic treatments. Therapies on the basis of antiangiogenic agents and inhibitors of the mammalian target of rapamycin have been approved for(More)
Fifteen percent of cancers are driven by oncogenic human viruses. Four of those viruses, hepatitis B virus, human papillomavirus, Merkel cell polyomavirus, and human T-cell lymphotropic virus, integrate the host genome. Viral oncogenesis is the result of epigenetic and genetic alterations that happen during viral integration. So far, little data have been(More)
Inter-tumor heterogeneity might explain divergent clinical evolution of cancers bearing similar pathological features. In the last decade, genomic has highly improved tumor subtypes classification through the identification of oncogenic or tumor suppressor drivers. In addition, epigenetics and long non-coding RNAs (lncRNAs) are emerging as new fields for(More)
Lung cancer accounts for 10% of cancer cases, but leads to 20% of cancer-specific mortality. Therapeutic options are limited, especially in tumors, which do not harbour druggable oncogenic alterations, and overall survival falls short of twoyears in the metastatic setting. The arrival of immunotherapy is a new hope for the achievement of an improved and(More)
Prediction of recurrence is a challenge for the development of adjuvant treatments in clear-cell renal cell carcinoma (ccRCC). In these tumors, expression of long non-coding RNAs (lncRNAs) are deregulated and closely associated with prognosis. Thus, we aimed to predict ccRCC recurrence risk using lncRNA expression. We identified prognostic lncRNAs in a(More)
Le congrès TAT (targeted anticancer therapies) est dédié aux essais précoces et aux molécules innovantes en cours de développement. La session 2016 a permis d’apercevoir le futur de l’immunothérapie antitumorale et des thérapies ciblées. Agir sur l’immunité antitumorale implique de relever de nombreux défis : mieux sélectionner les patients, comprendre les(More)
Le congrès Targeted Anticancer Therapies (TAT) s’est déroulé cette année du 2 au 4 mars à Paris. Encore une fois l’immunothérapie y était à l’honneur avec les anticorps anti-PD-1/PD-L1, les anticorps anti-CSF-1R, l’immunothérapie adoptive et le développement de combinaisons d’immunothérapies. Le challenge actuel reste de parvenir à identifier les patients(More)